Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2007-03-27
2007-03-27
Zara, Jane (Department: 1635)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S006120, C435S091100, C435S320100, C435S457000, C435S475000, C435S489000, C536S023100, C536S024320, C536S024500
Reexamination Certificate
active
10319341
ABSTRACT:
In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector. The methods can be used to express double stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, that interfere with a viral life cycle by down regulating either the viral genome, a viral genome transcript, or a host cell that. In another aspect the invention provides methods for treating patients having suffering from infection, particularly infection with HIV. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle.
REFERENCES:
patent: 5650309 (1997-07-01), Wong-Stall et al.
patent: 5883081 (1999-03-01), Kraus et al.
patent: 6060317 (2000-05-01), Malech
patent: 6096538 (2000-08-01), Kingsman
patent: 6218186 (2001-04-01), Choi et al.
patent: 6255071 (2001-07-01), Beach et al.
patent: 6274788 (2001-08-01), Kumar
patent: 6312956 (2001-11-01), Lane
patent: 6506559 (2003-01-01), Fire
patent: 6566083 (2003-05-01), Thastrup
patent: 6586208 (2003-07-01), Donahue
patent: 6635472 (2003-10-01), Lauermann
patent: 6664107 (2003-12-01), Mak
patent: 2003/0124513 (2003-07-01), McSwiggen
Banerjea Akhil et al., “Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages”, Molecular Therapy : The Journal of American Society of Gene Therapy, Jul. 2003, pp. 62-71, vol. 8, No. 1.
Barton G M et al., “Retroviral delivery of small interfering RNA into primary cells”, Proceeding of the National Academy of Sciences of USA, Nov. 12, 2002, pp. 14943-14945, vol. 99, No. 23, Washington, USA.
Brummelkamp T R, et al., “A system for Stable Expression of Short Interfering RNAs in Mammalian Cells,” Science, Apr. 19, 2002, vol. 296.
Caplen N J et al., “Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems,” PNAS, Aug. 14, 2001, vol. 98, No. 17.
Czauderna Frank et al., “Inducible shRNA expression for application in a prostate cancer mouse model”, Nucleic Acids Research, Nov. 1, 2003, p. e127, vol. 31, No. 21.
Devroe E. & Silver P A, “Retrovirus-delivered siRNA”, BMC Technology, Aug. 28, 2002, pp. 1-5.
Howard Hughes Medical Institute, “Pushing the Envelope” Nov. 21, 1997.
Jacque J-M et al., “Modulation of HIV-1 replication by RNA interference”, Nature, Jul. 25, 2002, pp. 435-438, vol. 418, No. 6896, London Great Britton.
Lawrence D “RNAi could hold promise in the treatment of HIV,” The Lancet, vol. 359, Jun. 8, 2002.
Lee N S et al., “Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells”, Nature Biotechnology, May 2002, pp. 500-505, vol. 19.
Li et al., “Inhibition of HIV-1 infection by lentiviral vectors expressing pol III-promoted anti-HIV RNAs”, Molecular Therapy, Academic Press, Aug. 2003, pp. 196-206, vol. 8, No. 2, San Diego, CA, USA.
Lois Carlos et al., “Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors”, Science, Feb. 1, 2002, pp. 868-872, vol. 295, No. 5556.
Martinez L J, “Katy, bar the door! HIV entry inhibitors,” Research/Initiative/Treatment Action! Jun. 2000.
Matsukura S et al., “Establishment of conditional vectors for hairpin siRNA knockdowns”, Nucleic Acids Research, Aug. 1, 2003, pp. e77-1, vol. 31, No. 15, Oxford University.
Miyagishi M et al., “U6 promoter-driven simas with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells”, Nature Biotechnology, May 2002, pp. 497-500, vol. 19, No. 5, US.
Miyoshi H. et al. “Development of a self-inactivating lentivirus vector”, Journal of Virology, 1998, pp. 8150-8157, vol. 72, No. 10.
Naldini, L. et al., “In VivoDelivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector” Science, vol. 272, Apr. 12, 1996.
National Cancer Institute, “Scientists Suggest New Approaches for Development of AIDS Drugs and Vaccines” Charity Wire, Jun. 21, 1999.
Novina C D et al., “siRNA directed inhibition of HIV-1 infection”, Nature Medicine, Jul. 2002, pp. 681-686, vol. 8, No. 7.
Ohkawa J. et al., “Control of the functional activity of an antisense RNA by a tetracycline-responsive derivative of the human U6 snRNA promoter”, Human Gene Therapy, Mar. 1, 2000, pp. 577-585, vol. 11, No. 4.
Paddison P J et al., “Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells” Genes & Development 16:948-958 Mar. 8, 2002.
Paul C P et al., “Effective expression of small interfering RNA in human cells”, Nature Biotechnology, May 2002, vol. 20, No. 5, US.
Pomerantz R J, “RNA interference meets HIV-1: Will silence be golden?” Nature Medicine, Jul. 2002, vol. 8, No. 7.
Qin X-F et al., “Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5”, Proceeding of the National Academy of Sciences of USA, Jan. 7, 2003, pp. 183-188, vol. 100, No. 1, Washington, USA.
Shankar P, “RNAi-Medicated Inhibition of HIV-1 Replication in Primary Macrophages” Center for Blood Research Boston.
Sirven A et al., “The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells”, W.B. Saunders Company, Dec. 15, 2000, pp. 4103-4110, vol. 96, No. 13, Orlando, Florida.
Sui G et al., “A DNA vector-based RNAi technology to suppress gene expression in mammalian cells”, Proceeding of the National Academy of Sciences of USA, Apr. 16, 2002, pp. 5515-5520, vol. 99, No. 8, Washington, USA.
University of Pennsylvania Health System: News and Periodicals, “Mutant Gene Products Strong Natural Resistance to HIV-1 Infection in 1 in 100 People,” Aug. 8, 1996.
Van De Wetering Marc et al., “Specific Inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector”, EMBO Reports, Jun. 2003, pp. 609-615, vol. 4, No. 6.
Yu Jenn-Yah et al., “RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells”, Proceeding of the National Academy of Sciences of USA, Apr. 30, 1002, pp. 6047-6052, vol. 99, No. 9, Washington, USA.
Zennou V et al., “HIV-1 Genome Nuclear Import is Mediated by a Central DNA Flap,” Cell, Apr. 14, 2000, vol. 101, 173-185.
Zufferey R et al., “Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors”, Journal of Virology, 1999, pp. 2886-2892, vol. 74, No. 4.
Arendt et al., “Vector Systems for the Delivery of Small Interfering RNAs: Managing the RISC**” ChemBioChem 2003, 4, pp. 1129-1136.
Lieberman et al., “Interfering with disease: opportunities and roadblocks to harnessing RNA interference,” Trends in Molecular Medicine, vol. 9, No. 9 Sep. 2003, pp. 397-403.
Yang Shi, “Mammalian RNAi for the masses,” Trends in Genetics, vol. 19, No. 1, Jan. 2003, pp. 9-12.
Brummelkamp et al., “A system for stable expression of short interfering RNAs in mammalian cells.” Apr. 19, 2002, vol. 296, pp. 550-553.
Chatterjee et al. “Dual-target inhibition of HIV-1 in virto by means of an adeno-associated antisense vector.” Science, Nov. 27, 1992, vol. 258, pp. 1485-1488.
Ilves et al. “Retroviral Vectors designed for targeted expression of RNA polymerases III-driven transcripts: a comparative study.” Gene. 1996. vol. 171, pp. 203-208.
Iwakuma et al., Self-inactivating lentilviral vectors with U3 and U5 mo
Baltimore David
Qin Xiao-Feng
California Institute of Technology
Knobbe Martens Olson & Bear LLP
Zara Jane
LandOfFree
Method for expression of small antiviral RNA molecules... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for expression of small antiviral RNA molecules..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for expression of small antiviral RNA molecules... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3732736